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Production of scientific work is regulated by reward systems. Scientists are typically 
rewarded for publishing articles, obtaining grants, and claiming novel, significant results. 
However, emphasis on publication can lead to least publishable units, authorship inflation, 
and potentially irreproducible results. Emphasis on claiming significant results leads to lack 
of publication of nonsignificant high-quality studies or to massaging data to obtain 
“positive” results. Emphasis on novelty leaves no incentives to spend resources on 
replicating prior findings to probe their correctness. Data owners have a publishing 
advantage without incentives to share with competitor scientists.
In the past, grapevine knowledge among the few knowledgeable experts allowed discerning 
the good work from the waste. But currently the noise-to-signal ratio is tremendous, with the 
proliferation of technologies (such as genomics) and journals. Thousands of new journals 
publish work for a fee, regardless of the quality of the work.1 To change the tide, the criteria 
by which scientists and their teams are rewarded for their efforts by agencies that fund them 
and institutions that host them should be revisited,2 aligning criteria with the desired 
outcomes: research that is productive, high-quality, reproducible, shareable, and 
translatable–or PQRST for short.
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Productivity metrics should reward high-influence science rather than least publishable units 
and decrease publication bias against negative results. Instead of counting each and every 
publishable unit, even now several major universities ask only for the top papers from each 
candidate for appointment or promotion. However, the process can be standardized. Citation 
databases such as ISI Web of Knowledge/Essential Science Indicators automatically identify 
scientific fields and the x% top-cited articles in each scientific field and each year (x can be 
set at 1%, 10%, or other desirable percentage). Authorship contributions should also be 
considered when allocating credit for multiauthored papers using standard formulas such as 
harmonic adjustments.3
Another useful metric is the proportion of published scientific work emanating from a 
research project. Funders can keep records of the publication of funded projects. Even for 
clinical trials funded by federal resources, a substantial proportion remain unpublished 
several years after their completion.4 For other types of research, nonpublication is likely to 
be even more frequent. Should investigators receive more funds if they used previous funds 
without publishing anything? In fields such as clinical research of interventions, public study 
registration has become widely accepted (and even enforced by regulatory agencies) and the 
concept of registration can be extended to other fields when appropriate.5 Registration 
allows documenting whether research studies result in published reports within a reasonable 
time of completion. Registration of protocols and analysis plans can also help evaluate 
selective reporting, ie, whether only some outcomes or analyses have been published and 
whether analyses deviate from promised plans.
For quality assessments, focusing on top-cited articles in assessing productivity already 
captures some aspects of quality, but citations and quality are not perfectly correlated. 
Funders can ask that protocols and studies fulfill specific quality standards in their design, 
implementation, and analysis. The National Institutes of Health is already moving in this 
direction with implementation of checklists.6 There are also numerous reporting standards 
for diverse research fields, as summarized by the EQUATOR initiative.7 Each field should 
agree on what quality features are essential. Nevertheless, difficulties in rating quality 
objectively should not be underestimated. Under pressure to comply, investigators may 
simply check off requested items while ignoring other fundamental issues relevant to the 
specific study. Quality assessments may focus on very few, uncontroversial, and easily 
verifiable study aspects. These assessments also may be used to promote improvement of 
that particular aspect in the whole field, eg, routine use of randomization and blinded 
assessments in preclinical animal studies.8
Reproducibility can range from repeating analyses with raw data to independent replication 
using different materials or study participants or even study designs different (more 
rigorous) than the original study. Some types of reproducibility checks are easy. Others are 
prohibitively difficult, eg, performing another similar trial with new participants and 10 
years of follow-up to independently replicate the results of a clinical study. This should be 
taken into account in deciding whether replication and reproducibility checks should be 
requested routinely (eg, when easy and inexpensive to do) or under select circumstances (eg, 
only for the most influential papers, if difficult and expensive to perform).
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Sharing can also be measured. For each scientist, it is possible to assess how many papers 
are accompanied by shareable data, materials, or protocols. Indexing databases such as 
PubMed and ClinicalTrials.gov could note in each new publication record whether such 
shared resources are available. Many funders and journals have already made sharing 
practices mandatory for particular research types.
As for translation, much excellent research has no recognizable translational application or 
benefit. Scientific influence, if any, often becomes manifest many years after the initial 
discovery. However, translational performance is relevant in research with direct applied 
aspirations, and this covers most of preclinical investigation and clinical medicine. For 
example, for preclinical studies of interventions, the translational milestone may be 
successful evaluation of the same intervention in humans; for clinical research, it may be 
licensing or approval for clinical use.
Given current resources, some of these indices can be easily evaluated for all scientists and 
for all their work. Other metrics and investigators need more focused appraisals; eg, it is 
impossible to perform reproducibility checks on every single published article. It is much 
easier to focus on the most influential articles, which are the ones considered in item P (eg, 
the top-cited 1%). A small budget is needed to reproduce articles that attain top scientific 
influence and thus have a major effect on the course of science. Many such articles already 
include replications, eg, currently all most-cited genome association studies include by 
default extensive replication in independent populations. Assessments of quality and 
translational influence that lack all-encompassing automated databases may also need to 
focus on the most influential work. Proportion of published work and assessments of sharing 
practices can relatively easily be automated science-wide by funders, registries, indexing 
online libraries, or other resources.
The Table illustrates some suggestions for how to potentially operationalize these principles. 
The suggestions are not prescriptive but may offer ideas to funders and other stakeholders 
for next practical steps. The exact combination or weighting of indices will require 
discussion and consensus among stakeholders. Selected reward system choices should also 
factor the potential for gaming any appraisal and reward system. Potential untoward 
consequences of gaming should be anticipated, minimized, and monitored. For example, 
scientists may acknowledge funding from specific grants for entirely unrelated published 
work if their career depends on demonstrating that funding resulted in publications. If so, 
funders should verify that the funded work has indeed been published. Or, if reward is given 
only for top-cited articles, networking between investigators and journals may create a 
citation factory of mediocre articles that mutually propel themselves toward the top-cited 
range. Some of the other indices will correct this; eg, observational nutritional epidemiology 
has some of the most-cited papers across all science, but much of this work has failed 
replication.
In addition, funding agencies, universities, research institutions, academies, professional 
societies, and prestigious award organizations may also have PQRST indices based on the 
research work they sponsor or perform and the scientists behind this work. Further 
discussion is needed among stakeholders to refine these indices and to evaluate them within 
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each scientific field. Special consideration will also be needed in rewarding research based 
on transdisciplinary team science that crosses the boundaries of multiple scientific 
disciplines.
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Table
PQRST Index for Appraising and Rewarding Research.
Item in PQRST Index
Operationalization
Example Data Source
P (productivity) Number of publications in the top tier % of citations 
for the scientific field and year
ISI Essential Science Indicators (automated)
Proportion of funded proposals that have resulted in 
≥1 published reports of the main results
Funding agency records and automated recording of 
acknowledged grants (eg, PubMed)
Proportion of registered protocols that have been 
published 2 y after the completion of the studies
Study registries such as ClinicalTrials.gov for trials
Q (quality of scientific 
work)
Proportion of publications that fulfill ≥1 quality 
standards
Need to select standards (different per field/design) and 
may then automate to some extent; may limit to top-cited 
articles, if cumbersome
R (reproducibility of 
scientific work)
Proportion of publications that are reproducible No wide-coverage automated database currently, but may 
be easy to build, especially if limited to the top-cited 
pivotal papers in each field
S (sharing of data and 
other resources)
Proportion of publications that share their data, 
materials, and/or protocols (whichever items are 
relevant)
No wide-coverage automated database currently, but may 
be easy to build, eg, embed in PubMed at the time of 
creation of PubMed record and update if more is shared 
later
T (translational influence 
of research)
Proportion of publications that have resulted in 
successful accomplishment of a distal translational 
milestone, eg, getting promising results in human 
trials for intervention tested in animals or cell 
cultures, or licensing of intervention for clinical 
trials
No wide-coverage automated database currently, would 
need to be curated by appraiser (eg, funding agency) and 
may need to be limited to top-cited papers, if cumbersome
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